SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced the acceptance of three late-breaking abstracts for poster presentation, including a poster presentation for tivumecirnon (FLX475), its lead oncology drug candidate, highlighting phase 2 clinical data in head and neck squamous cell carcinoma (HNSCC), at the American Association for Cancer Research (AACR) Annual Meeting which will take place April 5-10, 2024 in San Diego, CA.
Late-breaking poster presentation details:
Title: | Phase 2 Study of Oral CCR4 Antagonist FLX475 (tivumecirnon) Plus Pembrolizumab in Subjects with Head and Neck Squamous Cell Carcinoma (HNSCC) Previously Treated with Checkpoint Inhibitor | |
Abstract Number: | CT226 | |
Date & Time: | Tuesday, April 9, 2024; 9:00 a.m. ... |